Riemann D, Lis S, Fritsch-Montero R, Meier T, Krieger S, Hohagen F, Berger M
Psychiatric Department, University of Freiburg, Germany.
Biol Psychiatry. 1996 May 1;39(9):796-802. doi: 10.1016/0006-3223(95)00224-3.
The present study investigated the impact of the cholinesterase inhibitor tetrahydroaminoacridine (THA; tacrine) on sleep in healthy subjects. According to the reciprocal interaction model of non-rapid eye movement (NREM) and REM sleep regulation, which postulates a primary role in cholinergic neurotransmission for the initiation and maintenance of REM sleep, it was expected that THA would lead to an earlier onset of REM sleep. In 12 healthy subjects aged from 21 to 50 years two different doses (20 mg, 40 mg) were administered 1 hour prior to bed time and compared to placebo. Only the higher dose of THA significantly shortened REM latency. No other significant effects on sleep architecture were observed, although administration of 40 mg tacrine was associated with a decrease in sleep efficiency and a prolongation of sleep latency. Blood plasma levels of tacrine and its metabolite 1-hydroxytacrine measured prior to sleep and during the first 90 min of sleep were significantly correlated with the onset of REM sleep in relation to the timing of drug administration (only for the 20 mg dose). The reversible cholinesterase inhibitor THA exerts effects on REM latency comparable to those observed with other cholinomimetic agents.
本研究调查了胆碱酯酶抑制剂四氢氨基吖啶（THA；他克林）对健康受试者睡眠的影响。根据非快速眼动（NREM）和快速眼动（REM）睡眠调节的相互作用模型，该模型假定胆碱能神经传递在REM睡眠的起始和维持中起主要作用，预计THA会导致REM睡眠更早开始。在12名年龄在21至50岁的健康受试者中，在睡前1小时给予两种不同剂量（20毫克、40毫克），并与安慰剂进行比较。只有较高剂量的THA显著缩短了REM潜伏期。尽管给予40毫克他克林与睡眠效率降低和睡眠潜伏期延长有关，但未观察到对睡眠结构的其他显著影响。在睡眠前和睡眠的前90分钟测量的他克林及其代谢物1-羟基他克林的血浆水平与相对于给药时间的REM睡眠起始显著相关（仅对于20毫克剂量）。可逆性胆碱酯酶抑制剂THA对REM潜伏期的影响与其他拟胆碱药物观察到的影响相当。
